Product Description
a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders
Mechanisms of Action: H3 Inverse Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Sleep Disorders, Circadian Rhythm
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| LML134 | P1 |
Completed |
Healthy Volunteers |
2016-02-01 |
2019-03-20 |
Treatments |
|
| CLML134X2201 | P2 |
Terminated |
Sleep Disorders, Circadian Rhythm |
2018-08-30 |
21% |
2019-03-21 |
Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|